文献速递前列腺癌

减少前列腺癌患者过度治疗:基于欧洲前列腺癌筛查随机研究鹿特丹队列长期随访数据重新审视欧洲泌尿外科学会治疗前风险分组分类

Reducing Overtreatment of Prostate Cancer Patients: Revisiting the European Association of Urology Pretreatment Risk Group Classification Using Long-term Follow-up Data from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
PubMed 文献 · Eur Urol Oncol · 2024-11-26

本研究纳入筛查发现(1563例)和临床发现(755例)的局限性前列腺癌患者,比较欧洲泌尿外科学会(EAU)风险分类与按当代主动监测(AS)准入标准调整的替代分类预测15年前列腺癌特异性死亡(PCSM)的能力。EAU分类15年AUC分别为0.76和0.72,替代分类为0.74和0.75;替代分类在筛查队列和临床队列分别多识别45%和83%的低危男性,15年PCSM发生率无统计学显著增加。

要点

  • EAU分类预测PCSM准确,15年AUC在筛查队列为0.76、临床队列为0.72。
  • 按AS准入标准调整的替代分类多识别45%(筛查队列)和83%(临床队列)低危男性。
  • 替代分类低危组15年PCSM无统计学显著增加,可能提高AS接受度和使用率。

核心结论

  • EAU分类能准确预测PCSM,但按AS准入标准调整的替代分类可识别显著更多的低危男性,可能提高临床实践中AS的接受度和使用率,减少过度治疗。

研究设计与样本

  • 本研究纳入两个局限性前列腺癌队列:筛查发现队列(n=1563)和临床发现队列(n=755),均来自基于人群的随机筛查研究,接受初次根治性前列腺切除术或单纯放疗。
  • 患者按传统EAU风险分类和替代风险分类(低危按当代AS准入标准调整)进行分层,评估各分类和各队列的15年时间依赖AUC及诊断后15年PCSM累积发生率。

主要发现

  • 筛查队列中位随访20年、临床队列12年,EAU分类预测PCSM的15年AUC分别为0.76(95%CI 0.71-0.80)和0.72(95%CI 0.65-0.79)。
  • 替代分类15年AUC在筛查队列为0.74(95%CI 0.69-0.79),在临床队列为0.75(95%CI 0.68-0.81)。
  • 替代分类较EAU分类在筛查队列多识别45%的低危男性,在临床队列多识别83%的低危男性。
  • 替代分类低危组15年PCSM发生率无统计学显著增加:筛查队列亚风险比1.33(95%CI 0.66-2.68),临床队列亚风险比0.99(95%CI 0.29-3.38)。

关键数值与推荐

  • EAU分类预测PCSM的15年AUC:筛查队列0.76(95%CI 0.71-0.80),临床队列0.72(95%CI 0.65-0.79)。
  • 替代分类预测PCSM的15年AUC:筛查队列0.74(95%CI 0.69-0.79),临床队列0.75(95%CI 0.68-0.81)。
  • 替代分类较EAU分类低危男性多识别比例:筛查队列45%,临床队列83%。
  • 替代分类低危组15年PCSM亚风险比:筛查队列1.33(95%CI 0.66-2.68),临床队列0.99(95%CI 0.29-3.38)。

临床怎么用

  • 作者认为,采用按AS准入标准调整的替代分类可能提高临床实践中AS的接受度和使用率,从而减少过度治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Tailored treatment for prostate cancer (PCa) requires accurate risk stratification. This study examines the effectiveness of the European Association of Urology (EAU) classification in predicting long-term PCa-specific mortality (PCSM) and assesses whether an alternative system can improve the identification of patients with low-risk disease. METHODS: This study included two cohorts of patients with localized PCa: one with screen-detected PCa (n = 1563; S-cohort) and the other with clinically detected PCa (n = 755; C-cohort), all from a population-based, randomized screening study, who underwent primary radical prostatectomy or radiation monotherapy. Patients were stratified according to the traditional EAU risk classification and an alternative risk classification where low-risk disease is adjusted according to contemporary active surveillance (AS) eligibility criteria. The 15-yr time-dependent area under the curve (AUC) and the cumulative incidence of PCSM at 15 yr after diagnosis were assessed for each risk classification and cohort. KEY FINDINGS AND LIMITATIONS: With a median follow-up of 20 yr in the S-cohort and 12 yr in the C-cohort, the EAU classification demonstrated 15-yr AUCs of 0.76 (95% confidence interval [CI]: 0.71-0.80) and 0.72 (95% CI: 0.65-0.79), respectively, for predicting PCSM. The alternative classification showed a 15-yr AUC of 0.74 (95% CI: 0.69-0.79) in the S-cohort and 0.75 (95% CI: 0.68-0.81) in the C-cohort. The alternative classification identified 45% more men having a low risk in the S-cohort and 83% more in the C-cohort than the EAU classification, with no statistically significant increase in the 15-yr PCSM incidence (S-cohort subhazard ratio: 1.33 [95% CI: 0.66-2.68]; C-cohort subhazard ratio: 0.99 [95% CI: 0.29-3.38]). CONCLUSIONS AND CLINICAL IMPLICATIONS: The EAU classification predicts PCSM accurately, but an alternative classification, adjusted for AS eligibility, identifies substantially more men as having a low risk. This could enhance AS acceptance and utilization in clinical practice, reducing overtreatment. PATIENT SUMMARY: This study shows that while a commonly used pretreatment risk classification for prostate cancer predict disease prognosis accurately, an alternative system based on active surveillance eligibility criteria identifies many more men as having a low risk. Adopting this classification could enhance the acceptance and use of active surveillance, reducing unnecessary treatments.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. de Vos II, Rosenstand C, Hogenhout R, et al. Reducing Overtreatment of Prostate Cancer Patients: Revisiting the European Association of Urology Pretreatment Risk Group Classification Using Long-term Follow-up Data from the European Randomized Study of Screening for Prostate Cancer Rotterdam. Eur Urol Oncol. 2024. PMID: 39603883. doi:10.1016/j.euo.2024.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。